Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome

Modern Pathology

Volumn 21, Issue 12, 2008, Pages 1451-1460

  Yoshimoto, Maisa ^a   Joshua, Anthony M ^a   Cunha, Isabela W ^b   Coudry, Renata A ^b   Fonseca, Francisco P ^b   Ludkovski, Olga ^a   Zielenska, Maria ^c   Soares, Fernando A ^b   Squire, Jeremy A ^a,d  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b Hospital Do Câncer   (Brazil)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Biochemical recurrence; Biomarker; Interphase FISH; Prognosis; PTEN haploinsufficiency

Indexed keywords

ARTICLE; CANCER INVASION; CANCER RECURRENCE; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE; GENE DELETION; GENE FUSION; GENE LOSS; GENE REARRANGEMENT; GLEASON SCORE; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MALE; PERINEURAL INVASION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PTEN GENE; TMPRSS2 ERG GENE; TUMOR VOLUME;

EID: 56649091295     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.96     Document Type: Article

References (48)

1. Joshua AM, Evans A, Van der Kwast T, et al. Prostatic preneoplasia and beyond. Biochim Biophys Acta 2008;1785:156-181.
2. Hughes S, Yoshimoto M, Beheshti B, et al. The use of whole genome amplification to study chromosomal changes in prostate cancer: insights into genome-wide signature of preneoplasia associated with cancer progression. BMC Genomics 2006;7:65.
3. Yoshimoto M, Cutz JC, Nuin PA, et al. Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genet Cytogenet 2006;169:128-137.
4. Yoshimoto M, Joshua AM, Chilton-Macneill S, et al. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia 2006;8:465-469.
5. Besson A, Robbins SM, Yong VW. PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis. Eur J Biochem 1999;263:605-611.
6. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-241.
7. Cardone MH, Roy N, Stennicke HR, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998;282:1318-1321.
8. Ashcroft M, Ludwig RL, Woods DB, et al. Phosphorylation of HDM2 by Akt. Oncogene 2002;21:1955-1962.
9. Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004;10:594-601.
10. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999;96:857-868.
11. Trotman LC, Alimonti A, Scaglioni PP, et al. Identification of a tumour suppressor network opposing nuclear Akt function. Nature 2006;441:523-527.
12. Graff JR, Konicek BW, McNulty AM, et al. Increased AKTactivity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 2000;275:24500-24505.
13. Vivanco I, Palaskas N, Tran C, et al. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell 2007;11:555-569.
14. Koksal IT, Dirice E, Yasar D, et al. The assessment of PTEN tumor suppressor gene in combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma. Urol Oncol 2004;22:307-312.
15. Bertram J, Peacock JW, Fazli L, et al. Loss of PTEN is associated with progression to androgen independence. Prostate 2006;66:895-902.
16. Schmitz M, Grignard G, Margue C, et al. Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis. Int J Cancer 2007;120:1284-1292.
17. Yoshimoto M, Cunha IW, Coudry RA, et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 2007;97:678-685.
18. Tomlins SA, Mehra R, Rhodes DR, et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 2006;66:3396-3400.
19. Perner S, Demichelis F, Beroukhim R, et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006;66:8337-8341.
20. Cerveira N, Ribeiro FR, Peixoto A, et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 2006;8:826-832.
21. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-648.
22. Wang J, Cai Y, Ren C, et al. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 2006;66:8347-8351.
23. Ahlers CM, Figg WD. ETS-TMPRSS2 fusion gene products in prostate cancer. Cancer Biol Ther 2006;5:254-255.
24. Soller MJ, Isaksson M, Elfving P, et al. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer 2006;45:717-719.
25. Rajput AB, Miller MA, De Luca A, et al. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol 2007;60:1238-1243.
26. Attard G, Clark J, Ambroisine L, et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008;27:253-263.
27. Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007;26:4596-4599.
28. Nami RK, Sugar L, Wang Z, et al. Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol Ther 2007;6:40-45.
29. Winnes M, Lissbrant E, Damber JE, et al. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. Oncol Rep 2007;17:1033-1036.
30. Petrovics G, Liu A, Shaheduzzaman S, et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005;24:3847-3852.
31. Yoshimoto M, Ludkovski O, Bayani J, et al. Microdeletion and concurrent translocation associated with a complex TMPRSS2:ERG prostate cancer gene fusion. Genes Chromosomes Cancer 2007;46:861-863.
32. Ventura RA, Martin-Subero JI, Jones M, et al. FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue. J Mol Diagn 2006;8:141-151.
33. Korshunov A, Sycheva R, Gorelyshev S, et al. Clinical utility of fluorescence in situ hybridization (FISH) in nonbrainstem glioblastomas of childhood. Mod Pathol 2005;18:1258-1263.
34. Kawai T, Hiroi S, Nakanishi K, et al. Abnormalities in chromosome 17 and p53 in lung carcinoma cells detected by fluorescence in situ hybridization. Pathol Int 2004;54:413-419.
35. Mezzelani A, Alasio L, Bartoli C, et al. c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates. Br J Cancer 1999;80:519-525.
36. Mehra R, Tomlins SA, Shen R, et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 2007;20:538-544.
37. Tomlins SA, Laxman B, Dhanasekaran SM, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007;448:595-599.
38. Tomlins SA, Laxman B, Varambally S, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008;10:177-188.
39. Gopalan A LM, Satagopan JM, Zhou QC, et al. 97th Annual Meeting of the United States and Canadian Academy of Pathology. The United States and Canadian Academy of Pathology: Denver, Colorado, 2008.
40. Hsu T, Trojanowska M, Watson DK. Ets proteins in biological control and cancer. J Cell Biochem 2004;91:896-903.
41. Shukla S, Maclennan GT, Hartman DJ, et al. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int J Cancer 2007;121:1424-1432.
42. Kotelevets L, van Hengel J, Bruyneel E, et al. The lipid phosphatase activity of PTEN is critical for stabilizing intercellular junctions and reverting invasiveness. J Cell Biol 2001;155:1129-1135.
43. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene 2005;24:7443-7454.
44. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18 000 cancer gene expression profiles. Neoplasia 2007;9:166-180.
45. Lapointe J, Li C, Higgins JP, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004;101:811-816.
46. Glinsky GV, Glinskii AB, Stephenson AJ, et al. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004;113:913-923.
47. Maira SM, Galetic I, Brazil DP, et al. Carboxyl-terminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the plasma membrane. Science 2001;294:374-380.
48. Polette M, Mestdagt M, Bindels S, et al. Beta-catenin and ZO-1: shuttle molecules involved in tumor invasion-associated epithelial-mesenchymal transition processes. Cells Tissues Organs 2007;185:61-65.